News

Project ALS and Amylyx Pharmaceuticals will collaborate on preclinical studies of Amylyx’s lead compound AMX0035 as a potential treatment for patients with amyotrophic lateral sclerosis (ALS). These studies will complement Amylyx’s recently initiated Phase 2 CENTAUR clinical trial (NCT03127514), which will evaluate AMX0035 in 132 patients. Since mitochondrial…

Expression of the calcium channel Cacophony in certain motor neurons restored motor defects in a fruit fly model with TDP-43 loss, a condition found in  neurodegenerative diseases like amyotrophic lateral sclerosis (ALS) and frontotemporal dementia, a new study shows. The study, “Restoration of motor defects caused by loss…

The ALS Association of Georgia has received a $10,000 donation from William Mills Agency (WMA), an independent public relations and content marketing firm, to help the non-profit fund research and services to the local amyotrophic lateral sclerosis (ALS) community. William Mills lost its founder, William ‘Bill’ Mills Jr.,…

Option Care Enterprises will become a national provider of home infusion services for Radicava (edaravone), the first treatment for amyotrophic lateral sclerosis that the United States has approved in more than 20 years. Bannockburn, Illinois-based Option Care will provide the services under an agreement with Mitsubishi Tanabe Pharma America,…

The Boston prep school that ALS patient Pete Frates attended has recognized him for creating the Ice Bucket Challenge that has generated a tidal wave of funding for research on the disease. St. John’s Prep named Frates, who was diagnosed with amyotrophic lateral sclerosis in 2012 at the age of 27,…

The ALS Association has established a disaster relief fund to help patients and their families who were affected by Hurricane Harvey. Harvey brought strong winds and unprecedented rain that caused widespread flooding in parts of Texas and Louisiana. The Houston area recorded 20-plus inches of rain. A lot of people…

Clumps of the protein FUS, which are a pathological characteristic of ALS and frontotemporal dementia, can be prevented through a biological process called phosphorylation, a new study shows. The study, “Phosphorylation of the FUS low‐complexity domain disrupts phase separation, aggregation, and toxicity,” was published in the EMBO Journal. Phosphorylation…

Dutch researchers have identified new genes and biological mechanisms possibly involved in frontotemporal dementia (FTD) with and without amyotrophic lateral sclerosis (ALS). The study, “Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with Amyotrophic Lateral Sclerosis by DNA-methylation and GWAS,” appeared in the…

Levels of some microRNAs (MIRs) regulating re-innervation and muscle regeneration among amyotrophic lateral sclerosis (ALS) patients, while others are lower, an Italian study has found. These molecules help distinguish slow from rapid-progression ALS, and the findings suggest that therapeutic approaches targeting these MIRs may help delay disease progression. The study,…

Researchers at University of Exeter Medical School in the United Kingdom have started an ambitious project to investigate how mitochondria flaws may cause the neuron cell death associated with ALS. Not only may their insights provide a better understanding of how amyotrophic lateral sclerosis arises, but it also may…